{"id":"adt-standard-of-care","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Hot flashes"},{"rate":"70-90","effect":"Erectile dysfunction"},{"rate":"60-80","effect":"Decreased libido"},{"rate":"10-30","effect":"Gynecomastia"},{"rate":"30-50","effect":"Fatigue"},{"rate":"20-40","effect":"Bone loss / osteoporosis"},{"rate":"20-30","effect":"Weight gain"},{"rate":"5-15","effect":"Cardiovascular events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ADT is a standard-of-care hormonal therapy approach for prostate cancer that works by either reducing circulating testosterone levels (via GnRH agonists/antagonists or surgical castration) or blocking androgen receptor function (via antiandrogens). This starves androgen-dependent prostate cancer cells of the hormonal signals required for proliferation and survival.","oneSentence":"ADT (Androgen Deprivation Therapy) suppresses testosterone production or blocks androgen receptor signaling to inhibit growth of androgen-dependent prostate cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:17.988Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic hormone-sensitive prostate cancer"},{"name":"Locally advanced prostate cancer (in combination with radiation therapy)"},{"name":"Biochemically recurrent prostate cancer"}]},"trialDetails":[{"nctId":"NCT04633252","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-23","conditions":"Cancer Of Prostate, Prostate Neoplasms","enrollment":86},{"nctId":"NCT05658003","phase":"PHASE2","title":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-05","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":63},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":"Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer","enrollment":700},{"nctId":"NCT05477823","phase":"EARLY_PHASE1","title":"Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-03-08","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT06661122","phase":"","title":"A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-11-18","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Low-volume Metastasis","enrollment":100},{"nctId":"NCT07428642","phase":"","title":"PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.","status":"COMPLETED","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-09-01","conditions":"Metastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer","enrollment":168},{"nctId":"NCT07476001","phase":"PHASE2","title":"Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-03","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":12},{"nctId":"NCT04037254","phase":"PHASE1, PHASE2","title":"Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2019-10-08","conditions":"Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":22},{"nctId":"NCT03419234","phase":"PHASE2","title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2018-04-26","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue","enrollment":223},{"nctId":"NCT04720157","phase":"PHASE3","title":"An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-09","conditions":"Prostatic Neoplasms","enrollment":1145},{"nctId":"NCT06952803","phase":"PHASE3","title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-06","conditions":"Prostate Cancer","enrollment":700},{"nctId":"NCT06330805","phase":"PHASE2","title":"Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-08-12","conditions":"Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8","enrollment":70},{"nctId":"NCT07455903","phase":"PHASE2","title":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-04","conditions":"Prostate Cancer, Localized Prostate Carcinoma","enrollment":50},{"nctId":"NCT01409200","phase":"PHASE2","title":"Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-03-26","conditions":"Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7","enrollment":73},{"nctId":"NCT07206056","phase":"PHASE1, PHASE2","title":"An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-10-15","conditions":"Progressive Metastatic Castrate Resistant Prostate Cancer","enrollment":188},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":"Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer","enrollment":9},{"nctId":"NCT04443062","phase":"PHASE2","title":"Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-07-20","conditions":"Prostate Cancer","enrollment":58},{"nctId":"NCT04736199","phase":"PHASE3","title":"Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-23","conditions":"Prostatic Neoplasms","enrollment":669},{"nctId":"NCT05820932","phase":"","title":"Predicting Cognitive Decline From Androgen Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-05-22","conditions":"Prostate Cancer","enrollment":32},{"nctId":"NCT05720130","phase":"PHASE1, PHASE2","title":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","status":"RECRUITING","sponsor":"AdvanCell Pty Limited","startDate":"2023-03-15","conditions":"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer","enrollment":100},{"nctId":"NCT06305598","phase":"PHASE1","title":"Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2024-12-19","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":14},{"nctId":"NCT06111313","phase":"PHASE2","title":"The University of Miami Adapt (UAdapt) Trial","status":"RECRUITING","sponsor":"University of Miami","startDate":"2024-11-06","conditions":"Prostate Cancer","enrollment":130},{"nctId":"NCT04983095","phase":"NA","title":"Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Karin Soderkvist","startDate":"2021-10-27","conditions":"Prostate Cancer Metastatic, Radiation Therapy, Positron-Emission Tomography","enrollment":118},{"nctId":"NCT07389174","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mHSPC, mHNPC, Prostate Cancer Adenocarcinoma","enrollment":40},{"nctId":"NCT07325721","phase":"PHASE2","title":"Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-02-02","conditions":"Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy","enrollment":46},{"nctId":"NCT03543189","phase":"PHASE1, PHASE2","title":"Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-10-03","conditions":"Prostate Cancer, Prostate Disease","enrollment":44},{"nctId":"NCT06397703","phase":"PHASE2","title":"ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-04-16","conditions":"Prostate Cancer","enrollment":392},{"nctId":"NCT06825091","phase":"PHASE3","title":"Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE)","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-02-04","conditions":"Localized Prostate Cancer, Stereotactic Body Radiotherapy","enrollment":320},{"nctId":"NCT07344779","phase":"","title":"A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-02-17","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1600},{"nctId":"NCT04402151","phase":"PHASE2","title":"Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2020-06-30","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT06846320","phase":"PHASE2","title":"Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-29","conditions":"Generalized Anxiety Disorder (GAD)","enrollment":315},{"nctId":"NCT04126070","phase":"PHASE2","title":"Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiao X. Wei, MD","startDate":"2020-05-11","conditions":"Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma","enrollment":60},{"nctId":"NCT04267887","phase":"PHASE2","title":"Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-05-11","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":7},{"nctId":"NCT06039371","phase":"PHASE2","title":"Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-05-21","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":69},{"nctId":"NCT04870515","phase":"NA","title":"Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-11-04","conditions":"Localized Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":20},{"nctId":"NCT07310433","phase":"PHASE2","title":"Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Yung NA","startDate":"2026-06-01","conditions":"Prostate Cancer, Metastatic Prostate Cancer","enrollment":60},{"nctId":"NCT03523338","phase":"","title":"An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer","status":"NO_LONGER_AVAILABLE","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"","conditions":"Prostatic Neoplasms","enrollment":""},{"nctId":"NCT03511196","phase":"EARLY_PHASE1","title":"Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-09-17","conditions":"Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer","enrollment":17},{"nctId":"NCT06594926","phase":"PHASE2","title":"Working Out M0 Bipolar Androgen Therapy","status":"RECRUITING","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2024-08-14","conditions":"Prostate Cancer","enrollment":69},{"nctId":"NCT07164794","phase":"PHASE2","title":"Memantine Hydrochloride in Prostate Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Bin Xu","startDate":"2025-11","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)","enrollment":15},{"nctId":"NCT07237269","phase":"PHASE2","title":"Abiraterone/Prednisone + Standard ADT vs Standard ADT for Prostate Cancer Patients With PSMA-Positive Conventional Imaging Negative Pelvic Lymphadenopathy","status":"NOT_YET_RECRUITING","sponsor":"University of Nebraska","startDate":"2026-02-01","conditions":"Prostate Cancer","enrollment":140},{"nctId":"NCT04543799","phase":"","title":"Evaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer","status":"RECRUITING","sponsor":"Oncology Institute of Southern Switzerland","startDate":"2020-09-24","conditions":"Prostate Cancer, Breast Cancer","enrollment":60},{"nctId":"NCT02735252","phase":"NA","title":"PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2016-05-25","conditions":"Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma","enrollment":156},{"nctId":"NCT06536374","phase":"PHASE2","title":"Folate Study in Men With Advanced Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-06","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT06150417","phase":"PHASE2","title":"MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-07-01","conditions":"Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate","enrollment":200},{"nctId":"NCT03734653","phase":"EARLY_PHASE1","title":"Testosterone Therapy in Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-01-18","conditions":"Prostate Cancer, Castration-Resistant Prostate Cancer","enrollment":30},{"nctId":"NCT06274047","phase":"PHASE3","title":"PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-09-10","conditions":"Androgen Axis Suppression, Prostatectomy, Prostate Cancer","enrollment":120},{"nctId":"NCT07216248","phase":"PHASE2","title":"Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University of Utah","startDate":"2025-10-27","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","enrollment":160},{"nctId":"NCT06229236","phase":"NA","title":"Assessing Effectiveness of a Diabetes Navigator in Increasing Progression of Advanced Diabetes Technologies","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2024-02-13","conditions":"Diabetes Mellitus, Type 1","enrollment":148},{"nctId":"NCT02677896","phase":"PHASE3","title":"A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-03-09","conditions":"Metastatic Hormone Sensitive Prostate Cancer","enrollment":1150},{"nctId":"NCT06060587","phase":"PHASE2","title":"Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2023-10-19","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT06392841","phase":"PHASE2","title":"Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations","status":"WITHDRAWN","sponsor":"Qian Qin","startDate":"2025-10","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation","enrollment":""},{"nctId":"NCT06238596","phase":"NA","title":"Rehabilitation Intervention to Prevent Adverse Events Related to Androgen-deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer (PCa): a Single Arm Feasibility Study (ReCaP Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2023-09-06","conditions":"Metastatic Prostate Cancer (PCa) in ADT, Rehabilitation","enrollment":38},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":"Prostate Cancer Metastatic","enrollment":3360},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":"High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT05802121","phase":"EARLY_PHASE1","title":"Akkermansia Muciniphilia and Metabolic Side Effects of ADT","status":"RECRUITING","sponsor":"Western University","startDate":"2025-07-02","conditions":"Prostate Cancer, Metabolic Syndrome, Obesity","enrollment":30},{"nctId":"NCT07015138","phase":"NA","title":"Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-06-01","conditions":"Prostate Cancer, Oligometastatic Prostate Cancer","enrollment":390},{"nctId":"NCT07126860","phase":"NA","title":"The Effect of a Structured Strength and Endurance Training Program on Quality of Life, Fitness, Blood Parameters and Survival in Prostate Cancer Patients","status":"RECRUITING","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2024-05-24","conditions":"Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer (Post Prostatectomy)","enrollment":150},{"nctId":"NCT06202820","phase":"NA","title":"CV CARE: CardioVascular Care in PC Patients","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-01-18","conditions":"Prostate Cancer, Cardiovascular Diseases","enrollment":180},{"nctId":"NCT06625970","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-04-10","conditions":"High Risk Prostate Carcinoma, Prostate Cancer","enrollment":700},{"nctId":"NCT04115007","phase":"PHASE3","title":"Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-23","conditions":"Oligometastatic Hormone Sensitive Prostate Cancer","enrollment":550},{"nctId":"NCT06392295","phase":"PHASE2","title":"PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2024-07-03","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Hormone Sensitive Prostate Cancer","enrollment":34},{"nctId":"NCT06312670","phase":"PHASE2","title":"Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Pedro Barata, MD, MSc","startDate":"2024-05-16","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma","enrollment":13},{"nctId":"NCT02278185","phase":"PHASE2","title":"Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-11-11","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer","enrollment":19},{"nctId":"NCT06765954","phase":"PHASE2","title":"Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-06-01","conditions":"High-risk Prostate Cancer","enrollment":20},{"nctId":"NCT04619069","phase":"PHASE1, PHASE2","title":"Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2020-10-27","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT05169112","phase":"PHASE3","title":"Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-03-06","conditions":"Prostate Cancer","enrollment":72},{"nctId":"NCT02446405","phase":"PHASE3","title":"Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2014-03","conditions":"Prostatic Neoplasms","enrollment":1125},{"nctId":"NCT03127631","phase":"NA","title":"A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients","status":"RECRUITING","sponsor":"McMaster University","startDate":"2015-10-21","conditions":"Prostate Cancer, Cardiovascular Disease","enrollment":6000},{"nctId":"NCT05348577","phase":"PHASE3","title":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-03-25","conditions":"Prostate Cancer","enrollment":1035},{"nctId":"NCT02050906","phase":"NA","title":"Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2013-05-21","conditions":"Recurrent Prostate Cancer, Stage IV Prostate Cancer","enrollment":32},{"nctId":"NCT06496581","phase":"PHASE3","title":"Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-09-12","conditions":"Prostate Cancer Metastatic","enrollment":500},{"nctId":"NCT05404139","phase":"PHASE2","title":"Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-05-24","conditions":"Metastatic Prostate Cancer","enrollment":132},{"nctId":"NCT01985828","phase":"NA","title":"CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-11-19","conditions":"Prostate Adenocarcinoma","enrollment":83},{"nctId":"NCT04916613","phase":"PHASE3","title":"ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2022-04-19","conditions":"Prostate Cancer Metastatic","enrollment":300},{"nctId":"NCT03777982","phase":"PHASE3","title":"Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-04-20","conditions":"Prostate Cancer","enrollment":12},{"nctId":"NCT06585007","phase":"PHASE3","title":"Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-12-19","conditions":"Castration-resistant Prostate Cancer, Oligoprogressive","enrollment":246},{"nctId":"NCT03066154","phase":"PHASE1","title":"Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer","status":"TERMINATED","sponsor":"The Netherlands Cancer Institute","startDate":"2016-09","conditions":"Prostatic Neoplasms","enrollment":24},{"nctId":"NCT04465500","phase":"PHASE2","title":"EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2020-07-30","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":60},{"nctId":"NCT06305832","phase":"PHASE2","title":"Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-09-07","conditions":"Prostate Cancer, Biochemical Recurrence","enrollment":102},{"nctId":"NCT06177015","phase":"PHASE3","title":"Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-12-11","conditions":"Metastatic Prostate Cancer, Intermitent Anti-androgen Therapy","enrollment":200},{"nctId":"NCT03649841","phase":"PHASE2","title":"Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-06-29","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma","enrollment":10},{"nctId":"NCT01607879","phase":"PHASE2","title":"Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2014-03","conditions":"Prostate Cancer","enrollment":48},{"nctId":"NCT02895230","phase":"","title":"Androgen-Deprivation Therapy and Cardiovascular Risk: A Nationwide Population-based Cohort Study","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2016-01-01","conditions":"Prostate Cancer, Androgen-deprivation Therapy","enrollment":38690},{"nctId":"NCT04136353","phase":"PHASE3","title":"Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2020-03-31","conditions":"Prostate Cancer","enrollment":1100},{"nctId":"NCT03501173","phase":"","title":"A Study of Participants With Advanced Prostate Cancer in Canada","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2018-04-12","conditions":"Prostatic Neoplasms","enrollment":374},{"nctId":"NCT05209243","phase":"NA","title":"START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC","status":"RECRUITING","sponsor":"Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic","startDate":"2023-01-26","conditions":"Prostate Cancer, Stereotactic Body Radiation Therapy","enrollment":266},{"nctId":"NCT00268476","phase":"PHASE2, PHASE3","title":"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical Research Council","startDate":"2005-07-08","conditions":"Prostate Cancer","enrollment":11992},{"nctId":"NCT04748276","phase":"","title":"Tracking Response to Antidepressants in Advance of Investigational Trials","status":"UNKNOWN","sponsor":"Adams Clinical","startDate":"2019-01-02","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT05753566","phase":"PHASE2","title":"Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-03","conditions":"Prostate Cancer, Biochemical Recurrence","enrollment":96},{"nctId":"NCT04869371","phase":"PHASE2","title":"Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer","status":"UNKNOWN","sponsor":"Hongqian Guo","startDate":"2018-12-12","conditions":"Neoadjuvant Therapy \\ High Risk Prostate Cancer \\ Docetaxel","enrollment":75},{"nctId":"NCT04356430","phase":"PHASE2","title":"Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2019-04-01","conditions":"Prostate Cancer","enrollment":75},{"nctId":"NCT03879122","phase":"PHASE2, PHASE3","title":"A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer","status":"UNKNOWN","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2019-02-11","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":135},{"nctId":"NCT03739203","phase":"PHASE3","title":"The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-11-10","conditions":"Major Depressive Disorder","enrollment":752},{"nctId":"NCT04214353","phase":"NA","title":"PSMA-PET Imaging Before and After ADT in Advanced SDC Patients","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2020-01-14","conditions":"Salivary Gland Cancer, Salivary Duct Carcinoma","enrollment":14},{"nctId":"NCT04116775","phase":"PHASE2","title":"Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.","status":"UNKNOWN","sponsor":"Julie Graff, MD","startDate":"2019-10-30","conditions":"Prostate Cancer, Prostate Cancer Metastatic","enrollment":32},{"nctId":"NCT04331717","phase":"PHASE2","title":"Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-11-16","conditions":"Prostate Adenocarcinoma, Obesity, Morbid","enrollment":""},{"nctId":"NCT04446429","phase":"NA","title":"Anti-Androgen Treatment for COVID-19","status":"COMPLETED","sponsor":"Applied Biology, Inc.","startDate":"2020-10-21","conditions":"COVID-19, SARS-CoV2, Androgenetic Alopecia","enrollment":268},{"nctId":"NCT03424837","phase":"NA","title":"A Survivorship Care Plan and Embedded Navigation Tool","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-01-11","conditions":"Prostate Cancer","enrollment":77},{"nctId":"NCT04736108","phase":"PHASE2","title":"Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2021-05","conditions":"Prostate Cancer","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":284,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LHRH agonists","LHRH antagonists"],"phase":"phase_3","status":"active","brandName":"ADT (Standard of Care)","genericName":"ADT (Standard of Care)","companyName":"Aragon Pharmaceuticals, Inc.","companyId":"aragon-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ADT (Androgen Deprivation Therapy) suppresses testosterone production or blocks androgen receptor signaling to inhibit growth of androgen-dependent prostate cancer cells. Used for Metastatic hormone-sensitive prostate cancer, Locally advanced prostate cancer (in combination with radiation therapy), Biochemically recurrent prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}